Mebendazole shares a tubulin-inhibiting mechanism with established cancer drugs like Paclitaxel — which is why researchers have been investigating it in cancer contexts since the early 2000s. This factual guide covers what the laboratory research found, which actual human clinical trials have been registered, and why there is still a significant gap between research interest and clinical proof.

2025 has been a landmark year for cancer research. From an AI model predicting immunotherapy response from a routine blood test to personalised mRNA cancer vaccines reducing recurrence risk by 44 percent — here are the 7 biggest verified breakthroughs of the year, what they mean, and what they could mean for patients.

Taken your ivermectin dose and wondering what comes next? This complete day-by-day timeline explains exactly when ivermectin starts working, what the die-off reaction is, why itching gets worse before it gets better with scabies, when to take the second dose, and what full recovery looks like — week by week.

A dog deworming drug sparking global cancer treatment conversations — is fenbendazole the breakthrough patients are hoping for, or dangerous misinformation? This evidence-based guide covers the latest 2026 research, real risks, and what cancer patients in India need to know before considering it.

In 2016, Joe Tippens was given three months to live with terminal small-cell lung cancer. Three months later, his PET scan showed no cancer. As of January 2026, he is still alive — 10 years in complete remission. This complete 2026 guide covers the original protocol with exact dosages, the full 2024–2026 updated version with Ivermectin and new supplements, the science behind every component, honest research evidence, mandatory liver monitoring rules.

Ivermectin and Fenbendazole are the two most searched antiparasitic cancer protocol drugs in 2026 — but they work through completely different mechanisms and suit different cancer types. Fenbendazole attacks cancer's structural and metabolic foundations; Ivermectin unmasks cancer cells from the immune system via PD-L1. This complete comparison covers the ICONIC trial update, 716-case series, full protocol frameworks, the cancer-type match guide, price table.

Febentel Plus combines Fenbendazole 500mg and Ivermectin 25mg — the two most searched antiparasitic cancer protocol drugs in the world in 2026 — into a single pharmaceutical-grade tablet. With 700+ documented cancer cases, an active ICONIC Phase I/II clinical trial, and the 2026 Dr. Makis protocol now guiding thousands of patients globally, this complete guide covers the full protocol tables, 12 Fenbendazole anticancer mechanisms, Ivermectin's PD-L1 immune checkpoint action.